Difference between revisions of "CDX2"
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
*[[Ovarian mucinous adenocarcinoma]] +ve.<ref name=pmid14668551/> | *[[Ovarian mucinous adenocarcinoma]] +ve.<ref name=pmid14668551/> | ||
*[[Lung adenocarcinoma]] -ve (<5% +ve in 20 cases<ref name=pmid17549351>{{Cite journal | last1 = Tanaka | first1 = S. | last2 = Saito | first2 = K. | last3 = Ito | first3 = T. | last4 = Tajima | first4 = K. | last5 = Mogi | first5 = A. | last6 = Shitara | first6 = Y. | last7 = Sano | first7 = T. | last8 = Kuwano | first8 = H. | title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. | journal = Oncol Rep | volume = 18 | issue = 1 | pages = 87-92 | month = Jul | year = 2007 | doi = | PMID = 17549351 }}</ref>). | *[[Lung adenocarcinoma]] -ve (<5% +ve in 20 cases<ref name=pmid17549351>{{Cite journal | last1 = Tanaka | first1 = S. | last2 = Saito | first2 = K. | last3 = Ito | first3 = T. | last4 = Tajima | first4 = K. | last5 = Mogi | first5 = A. | last6 = Shitara | first6 = Y. | last7 = Sano | first7 = T. | last8 = Kuwano | first8 = H. | title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. | journal = Oncol Rep | volume = 18 | issue = 1 | pages = 87-92 | month = Jul | year = 2007 | doi = | PMID = 17549351 }}</ref>). | ||
*[[Yolk sac tumour]] (8 of 20 cases - versus glypican-3).<ref name=pmid19578052>{{Cite journal | last1 = Bing | first1 = Z. | last2 = Pasha | first2 = T. | last3 = Tomaszewski | first3 = JE. | last4 = Zhang | first4 = P. | title = CDX2 expression in yolk sac component of testicular germ cell tumors. | journal = Int J Surg Pathol | volume = 17 | issue = 5 | pages = 373-7 | month = Oct | year = 2009 | doi = 10.1177/1066896909338598 | PMID = 19578052 }}</ref> | |||
==References== | ==References== | ||
{{Reflist|1}} | {{Reflist|1}} | ||
[[Category:Immunohistochemistry]] | [[Category:Immunohistochemistry]] | ||
Revision as of 17:14, 30 December 2014
CDX2 is a commonly used immunostain.
Normal
- Intestinal epithelium.[1]
Pathology
- Intestinal adenocarcinomas +ve.
- Colorectal adenocarcinoma.
- Small bowel adenocarcinoma +ve/-ve (~43% +ve in series of 189 cases[2]).
- Ovarian mucinous adenocarcinoma +ve.[1]
- Lung adenocarcinoma -ve (<5% +ve in 20 cases[3]).
- Yolk sac tumour (8 of 20 cases - versus glypican-3).[4]
References
- ↑ 1.0 1.1 Groisman, GM.; Meir, A.; Sabo, E. (Jan 2004). "The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.". Int J Gynecol Pathol 23 (1): 52-7. doi:10.1097/01.pgp.0000101141.31270.a0. PMID 14668551.
- ↑ Jun, SY.; Eom, DW.; Park, H.; Bae, YK.; Jang, KT.; Yu, E.; Hong, SM. (Mar 2014). "Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma.". Mod Pathol. doi:10.1038/modpathol.2014.36. PMID 24603585.
- ↑ Tanaka, S.; Saito, K.; Ito, T.; Tajima, K.; Mogi, A.; Shitara, Y.; Sano, T.; Kuwano, H. (Jul 2007). "CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens.". Oncol Rep 18 (1): 87-92. PMID 17549351.
- ↑ Bing, Z.; Pasha, T.; Tomaszewski, JE.; Zhang, P. (Oct 2009). "CDX2 expression in yolk sac component of testicular germ cell tumors.". Int J Surg Pathol 17 (5): 373-7. doi:10.1177/1066896909338598. PMID 19578052.